Pomerantz Law Firm Launches Investigation for Unicycive Therapeutics Investors Following Significant Stock Drop

Pomerantz Law Firm Investigates Unicycive Therapeutics

The Pomerantz Law Firm, known for its leadership in corporate and securities class action litigation, has announced its investigation of claims on behalf of investors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY). This investigation arises in light of a significant drop in the company’s stock prices following adverse news regarding their New Drug Application (NDA).

Unicycive, a biopharmaceutical company focused on addressing unmet medical needs in kidney disease, recently issued a press release on June 30, 2025, revealing that the U.S. Food and Drug Administration (FDA) has delivered a Complete Response Letter (CRL) concerning its NDA for OLC, a drug intended to treat hyperphosphatemia in chronic kidney disease (CKD) patients undergoing dialysis. This CRL was triggered by deficiencies cited during a cGMP inspection of a third-party manufacturing vendor, which raised concerns about compliance with manufacturing regulations.

As a result of this announcement, the share price of Unicycive plummeted by $2.03 per share, which translates to a staggering 29.85% decline, closing at $4.77 per share on the same day. This abrupt decrease in value has prompted Pomerantz LLP to gather information from investors regarding possible securities fraud or unlawful business practices by the company and its executives.

The law firm encourages any investors of Unicycive Therapeutics who may be affected to reach out to them directly for guidance and potential participation in a class action lawsuit. Pomerantz’s reputation for representing the rights of investors in securities class actions has been well-established for over 85 years, and the firm continues to advocate for victims of corporate misconduct and breaches of fiduciary duty.

To join the investigation or inquire further, unaffected investors are advised to contact Danielle Peyton of Pomerantz LLP via email at [email protected] or by phone at 646-581-9980, ext. 7980.

The significance of this investigation cannot be understated, especially considering the troubled pathway for many biopharmaceutical companies navigating regulatory approvals. A CRL from the FDA often signals more than just a setback; it can indicate deeper issues underlying a company’s operations that investors must consider. Companies like Unicycive, despite their innovative potential, face significant scrutiny that can directly affect their market performance and investor confidence.

Pomerantz LLP continues to be a leading player in fights against securities fraud and corporate malfeasance, dedicated to recovering damages on behalf of affected investors. The firm’s steady commitment reflects in their track record, having secured numerous multimillion-dollar settlements for class members over decades of practice.

For updates regarding the situation with Unicycive Therapeutics and for those interested in the broader conversations around investing in biotechnology firms, staying informed through such alerts can be crucial. Investors must remain vigilant, particularly in times of regulatory focus that may influence market dynamics.

In conclusion, the Pomerantz Law Firm's proactive stance in investigating these claims underscores the essential need for transparency and accountability in financial markets, especially within sectors where the stakes and investments are incredibly high. Investors who suspect they have been impacted by Unicycive's recent developments are urged to act swiftly to understand their rights and options in this evolving landscape.